Kukushkin S K, Lebedev A V, Manoshkina E M, Shamarin V M
Ter Arkh. 1998;70(9):69-71.
The study of the effects of the inhibitor of angiotensin converting enzyme ramipril (tritace) on the 24-h profile of blood pressure (BP) in patients with mild and moderate arterial hypertension.
Ramipril was given to 21 males aged 45-68 years with essential hypertension stage II (WHO criteria) with stable elevated diastolic blood pressure (95-114 mm Hg) in a single dose 2.5-10 mg/day. Captopril controls received 100 mg twice a day. BP was monitored using "SpaceLabs Medical" unit (model 90207, USA).
Compared to placebo, ramipril lowered systolic and diastolic blood pressure both for the 24-h period and in the day time; captopril lowered only diastolic BP in the day time. Side effects of long-term application of ramipril occurred 2 times less frequently than in application of captopril.
Long-term treatment with ramipril in the above regimen provides more effective control of BP than captopril in the above doses in patients with mild and moderate hypertension.
研究血管紧张素转换酶抑制剂雷米普利(捷赐瑞)对轻、中度动脉高血压患者24小时血压(BP)变化情况的影响。
对21名年龄在45 - 68岁的男性原发性高血压II期患者(符合WHO标准)进行研究,这些患者舒张压持续升高(95 - 114毫米汞柱),给予雷米普利单剂量每日2.5 - 10毫克。卡托普利对照组患者每日两次,每次100毫克。使用“太空实验室医疗”设备(美国90207型号)监测血压。
与安慰剂相比,雷米普利在24小时期间及白天均降低了收缩压和舒张压;卡托普利仅在白天降低了舒张压。长期应用雷米普利的副作用发生率比应用卡托普利低两倍。
对于轻、中度高血压患者,采用上述方案长期使用雷米普利比使用上述剂量的卡托普利能更有效地控制血压。